Satellite symposium

Molecular aspects of metal-anticancer drugs

December 2nd, 2007

during ISPCC

9.00 am – 16.30

Session 1
(Pre-)Clinical status of new Pt and Ru drugs
Chairman: Jan Reedijk, The Netherlands

9.00   Preclinical status and clinical development of new non platinum antitumor drugs
Bernhard Keppler, Austria

9.30   Clinical and Pre-clinical Status of Emerging Platinums
Nicholas Farrell, USA

Session 2
New types of Metal-DNA binding
Chairman: Wolfgang Weigand, Germany

10.00 Non-coordinating metal complexes that bind to nucleic acids
Mike Hannon, United Kingdom

10.30  Coffee break

Session 3
Telomerase inhibition by Pt and other compounds
Chairman: Stephen J Lippard, USA

11.00 Platination of telomeric DNA: towards the destabilisation of telomers
Sophie Bombard, France

11.30 Nucleobase Quartets as Novel Targets for Metal Drugs
Bernhard Lippert, Germany

Session 4
Molecular details of recognition and repair of DNA damage by platinum and ruthenium antitumor drugs
Chairman: Stephen G Chaney, USA

12.00 Interaction of the DNA mismatch repair protein MutS with cisplatin-modified DNA: molecular basis for DNA damage signalling
Jean-Marc Malinge, France

12.30 Nucleotide excision repair of DNA cross-links of platinum complexes
Viktor Brabec, Czech Republic

13.00  Lunch

Session 5
Platinum compounds coordinating to non-DNA sites
Chairman: Luigi Messori, Italy

14.00 Interactions of Pt complexes with cell extracts
Dan Gibson, Israel

14.30 Platinum Drug Uptake in Tumours, Tumour Models and Cells: Imaging and Modification
Trevor Hambley, Australia

15.00  Coffee-break

Session 6
New chemistry approaches for novel Pt and Ru anticancer drugs
Chairman: Carmen Navarro, Spain

17.30 Activation and cytotoxicity of light-activated diazido-Pt(IV) complexes as potential anticancer drugs
Patrick Bednarski, Germany

16.00 Platinum(II) Metallointercalators with Potent in vitro Cytotoxic Activity
Janice Aldrich-Wright, Australia

16.30 Closure, and start of the ISPCC yes/no panel (Session VI)